Bioelectronics Corp. (Pink Sheets: BIEL)

Dear Reader,

Today's featured company is at the leading edge of its technology. We've all heard the stories about sports stars that pull a muscle and the team trainer attaches a pulsating, apparatus on their calf to reduce the discomfort, stimulate the area with electronic beats, and lead the affected area into the healing process. 

BioElectronics provides a similar product line, but for consumers. You don't need a professional trainer or have to belong to the NBA, or NFL, or the Professional Golf Association to ease your aches and pains.  Like NASA bringing microwave technology to the masses, here is sports medicine now made available to everyday people.

We like the innovation at this company and the practicality of its products. BioElectronics is taking proven medical technologies and making them available to more people in convenient, cost-effective dermal patches.  By applying advanced microelectronic technology, BioElectronics is dramatically reducing the size and the cost of some well-established medical treatments.  Ever had an ache or a pain?  Sure, we all have.  Please take a look at BioElectronics. 
aa

About BioElectronics

a

BioElectronics Corporation ("BIEL") designs, manufactures and markets, under the trade name ActiPatchTherapy, a variety of proprietary, drug-free, anti-inflammatory patches that accelerate healing for a broad range of medical indications. BIEL is developing new products for repetitive stress injuries, such as heel pain, carpal tunnel, back pain, sprains and strains and chronic wounds.

The patches are embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, patient friendly method to reduce soft tissue pain and swelling.

BIEL products deliver pulsed electromagnetic frequency (PEMF) therapies to accelerate healing and a reduction of pain and swelling allows patients to return to normal activities much sooner.  The BIEL ActiPatch is FDA approved and affordable. Instead of paying $100 for a single treatment at a clinic or a hospital, ActiPatch Therapy provides 10 days of treatment for $49.95. 
 
 

BIEL Markets and Marketing

Pharmaceutical or electrotherapeutic research yields its most effective and efficient results when it employs existing technologies to create advanced product developments and breakthroughs. BIEL is in the business of putting proven medical technology into advanced miniaturized electronics to create convenient, efficacious, and cost-effective therapies.

Therapeutic needs of the 200 mil. annual tissue injuries in the U.S. (75 mil. surgical procedures, 87 oral surgeries, 45 mil. sprains and strains, and other accidents) is obvious. The specific disease states targeted for inclusion within the product spectrum include surgical and accidental wounds, chronic wounds,
sprains and strains, bone fractures, and arthritis pain. 

BIEL’s products are a technical breakthrough at a market disruptive price point. The existing U.S. market for ActiPatch Therapy's suite of products exceeds $6.5 bil. annually and $20 bil. worldwide. BIEL’s advanced technology platform will effectively “change the way people heal”.

• Orthopedic Group, strains, sprains and chronic pain strains, sprains and chronic pain
• Orthopedics, Podiatry, Chiropractic, Occupational/Physical Surgical Group 
• Wound Care Wound Care – acute and chronic acute and chronic
• Hospitals, Long Term Care facilities, plastic surgery and Long Term Care facilities

• Heel pain device inserted into foot care pads or orthopedic devices 
• Product bundling with with ActiPatchGauze padded wound dressing with ActiPatch®
• Reseller/Distributor Reseller/Distributor
• Co-labeled products that leverage existing distribution channels 
• Direct mail and follow up on telemarketing with web fulfillment reorders
• Direct sales calls to major hospitals, long-term care, outpatient clinics, 
• Develop relationships with major health systems marketing to government and unions 

• Direct Sales to Physicians Direct Sales to Physicians
• Independent Sales Agents Network
• Reseller Distribution Agreements 
• Retail – Over-the the-Counter Consumer Sales 
• Partnering – Embedded Technology Applications

Night Time Therapy

BIEL products are currently in a 10-store test by Scholl’s Foot Care Centers in the United Kingdom to mount a resume' of clinical evidence of efficacy from practice. Other clinical evidence of efficacy from practicing physicians at medical schools include: Northwestern University Temple Unisurgeons, the University of Wisconsin, and New York State University. BIEL products are also used by major professional teams including     the Baltimore Ravens. BIEL has established the use of ActiPatch by a number of professional sports teams and formed its Sports Medicine Advisory Committee headed by Herm Schneider, Head Trainer Chicago White Sox. This committee includes members from leading professional athletic teams.

BIEL is currently conducting field clinical trials with participating podiatrists around the country. Your doctor may be participating or you may want to invite her to participate.  As part of our clinical evaluation, if ActiPatch does not work for you, simply return it to your doctor and we will send a full refund check. 

In March 2006,  the Company formulated its research and development relationship with the Lahey Clinic. The Lahey Clinic Medical Center is a teaching hospital for Tufts University School of Medicine. In addition, many of its physicians hold teaching assignments at Harvard Medical School and Boston University School of Medicine.  As a research center, Lahey Clinic has conducted research for over 26 years on new therapies for diseases such as cancer, diabetes, heart disease and advanced and innovative surgical techniques.  Research programs at Lahey Clinic encompass more than 300 active clinical trial protocols and successful completion of 2,200 pharmaceutical studies. The Lahey Clinic is doing clinical research and studies on the use of ActiPatch Therapy for ankle sprain, carpal tunnel, body contouring, and wounds.
a

The Bandage That Heals

a

      * Provides a portable device for a quicker and more convenient application of therapy, and to improve patient compliance;
    * Dramatically lowers the cost of therapy to less than $5.00 per day;
    * Eliminates the need for a trained operator and recurring office visits for treatment;
    * Uses the body's own electrical properties and reduces the 117 VAC, 60 Hz, 5 Amps requirements of existing devices to a 3-volt DC battery; and,
    * Simplifies the method of use from variable power and pulse frequencies to a fixed treatment setting.
 

ActiPatch Produces controlled involuntary muscle contractions, helping to speed recovery of normal muscle function, reducing pain, relieving spasms and preventing atrophy. ActiPatch Can Replace More Expensive Therapies Including Bone Growth Stimulators - Muscular Stimulators Ultrasound - Diathermy

When the body receives an injury during surgery, or from trauma such as a sprain, there is little danger of infection.  Nevertheless, the body’s response is to inflame the injured tissue to prevent infection. This inflammatory first phase of healing is evidenced by redness, heat, swelling and pain in the tissue. To reduce the swelling, relieve the pain and accelerate healing, ActiPatch induces the tissue to rapidly pass through, or by-pass, the inflammatory process and move to the repair phase. In chronic wounds and repetitive stress injuries such as plantar fasciitis (heel pain), carpal tunnel syndrome, tennis elbow, etc. the inflammatory phase of healing is stalled. ActiPatch Therapy breaks the cycle of inflammation and allows the injury to heal. Drug-free healing and pain relief is accomplished by shortening or breaking the inflammatory healing cycle.

Management at BIEL

Andrew J. Whelan - President and Chief Executive Officer, and Chairman

Mr. Whelan is a seasoned business executive with a strong financial, consulting, and management background. He was a founder, Chairman, and President of Physicians' Pharmaceutical Services, Inc., a public company, and a charter member of the Maryland Chapter of Inc's Fastest Growing Companies in America. Mr. Whelan was also a founder, President, and CEO of Drug Counters, a chain of managed care retail pharmacies, which was sold to Diagnostek, Inc.

Thomas J. O'Connor - Vice President, Operations, Chief Financial Officer, Secretary & Director

Mr. O'Connor has served as Vice President Operations, Chief Financial Officer, Secretary and as a director of the Company since October 8, 2004.  Mr. O'Connor received his bachelor of arts and masters of business administration and finance from Arizona State University. Mr. O'Connor served as Chief Operating Officer of the start-up team recruited in 1994 to develop CVS Corporation's prescription benefits management subsidiary and bring it to its current $2.0 billion per year revenue status. Prior to joining CVS, Mr. O'Connor held progressive positions in finance, systems development and marketing at PCS Health Systems.  Additionally, Mr. O'Connor served as an independent consultant providing his e-health, emarketing, product development and marketing expertise to such clients as WebMD Corporation, Healtheon, Inc., ComCoTec, Inc. and Pharmaceutical Care Network

Joe Iglesias - Vice President Design and Engineering

Joe brings over fifteen years of product design, engineering and management experience in medical devices. He is a specialist in bioengineering and ergonomic design. Joe has designed and developed more than 20 innovative products in the fields of orthopedics, sports medicine, podiatry, chronic wound care and rehabilitation that have resulted in more than 25 patents in the US and worldwide. Joe received his BSME from University of California at Santa Barbara. Formerly, Joe was the Manager of Product Design for Royce Medical.

Wayne Gillis - International Business Development

Mr. Gillis has over twenty years of experience in the investment field. He is President and founder of Sherwood Financial Corp., which specializes in offshore investments and raising capital for startup firms in the technology sector. He also has an extensive background in the single-payer Health Care environments and has worked on projects with IBM and a number of pharmaceutical firms. He was educated at Dalhousie University, Bachelor of Commerce, Saint Mary's University, Bachelor of Science, Engineering, and NSCAD Industrial Design.

The BIEL Medical Advisory Board is staffed by world renowned medical researchers, and professors from top tier medical schools and research institutions.
a

Recent News  from BioElectronics

Press Release Source: BioElectronics Corporation
Thursday June 8, 9:00 am ET

FREDERICK, Md., June 8 /PRNewswire-FirstCall/ -- BioElectronics Corporation (Pink Sheets: BIEL - News) CEO Andrew Whelan expressed on behalf of the company its frustration at the unauthorized and unsolicited e-mail campaign that appears to have been widely distributed featuring BIEL's stock symbol.

This SPAM e-mail campaign was initiated without our knowledge. We did not pay for it nor assist in any way," said Whelan. "In fact, it's been a true struggle for us to deal with the wrongful assumption by many individuals who received this SPAM that the company is behind it. We are indeed a victim too and empathize with those who have received this junk. It was sent to our personal e-mail boxes as well."

"And to the spammers, we are working with our counsel and investigators to determine who is behind this and will take appropriate action," Whelan added. "We are committed to ethical and honorable investor relations on behalf of this fine company. We needn't be sullied by such illicit activity and will not stand for this unwanted corporate graffiti bearing our good name."

The recent SPAM featuring BioElectronics Corporation may also be in violation of the federal CAN-SPAM Act of 2003 signed into law by President Bush on December 16, 2003. 

To read the complete release and disclaimer, Click Here
a

FREDERICK, Md., June 6 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL - News), announced today that the design for a new retail foot care product has been finalized with ProFoot, Inc. for distribution of the ActiPatch(TM) product in Canada. The new product is expected to be available in retail stores and pharmacies throughout Canada by the end of the summer.

ActiPatch(TM), which is approved by Health Canada, is a drug-free, anti- inflammatory patch for the relief of pain from stress, strains and sprains. Specifically, the ActiPatch will be marketed through the ProFoot(TM) line of foot care products for the relief of such foot conditions as plantar fasciitis, heel spur and arch pain.

"We are pleased that we have completed the all important design phase and will now be moving into the production phase. We value our partnership with ProFoot, Inc. and we are committed to bring this product to the retail market to bring relief to thousands of people who suffer from debilitating foot conditions," said BioElectronics Corporation, CEO Andrew Whelan.

Thomas O'Connor, BioElectronics Corporation's COO further commented, "The speed with which we have been able to design and build a new product speaks highly on our development platform and capabilities. We are looking forward to continuing to build new products for highly respected companies such as ProFoot, Inc. They are a great organization to be associated with and we look forward to making our retail partnership a big success in Canada, Europe and the United States." 

To read the complete release and disclaimer, Click Here

FREDERICK, Md., May 16 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL - News), announced today that the company filed a 510(k) Market Clearance application for its new ActiPulse(TM) device with the Food and Drug Administration. ActiPulse(TM) requested indication for use is "the adjunctive use in the palliative treatment of post operative pain and edema in superficial soft tissue."

Andrew J. Whelan, President, stated, "This new device will broaden our sales and market scope into palliative treatment of postoperative edema and pain in superficial soft tissues."

BioElectronics currently manufactures and sells ActiPatch(TM), a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost- effective, patient friendly method to reduce soft tissue pain and swelling.

This device is currently investigational and not cleared for sale by the FDA, nor is it currently available for purchase in the United States.

To read the complete release and disclaimer, Click Here
>>

Financial Highlights For BioElectronics

a

Last Trade: 0.16 (06-28-06) 52wk Range: 0.16 - 0.54 Avg Vol (3m): 135,772 Market Cap: 10.18M Float: 5,000,000 (as of 2005-02-14) Fiscal Year End: December 31 State of Incorporation: Maryland

TO CONTACT BIEL

---

*** The Bull is Running. ***
There may never be a better time to feature YOUR company
to over 1 MILLION investors.

To learn more about our programs email us directly at info@stockupticks.com

Disclaimer: StockUpTicks.com is a property of Market Pathways Financial Relations Incorporated (MP).  The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Past performance is no guarantee of future results. This report is a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision.  MP has been paid five thousand dollars and has been granted one hundred fifty thousand free trading shares by BioElectronics Corp. for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP’s ability to remain objective in its communication regarding the subject company.  Write or call MP for detailed disclosure as required by Rule 17b of the Securities Act of 1933/1934 - Market Pathways 17595 Harvard Ave., Suite C519 Irvine, CA  92614.  MP is not an investment advisor and this report is not investment advice. This information is neither a solicitation to buy nor an offer to sell securities but is a paid advertisement.  Information contained herein contains forward-looking statements and is subject to significant risks and uncertainties, which will affect the results.  The opinions contained herein reflect our current judgment and are subject to change without notice. MP and/or its affiliates, associates and employees from time to time may have either a long or short position in securities mentioned.  Information contained herein may not be reproduced in whole or in part without the express written consent of Market Pathways Financial Relations Incorporated.